Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours): lines of therapy
4 standard-of-care settings across 1 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers |
|---|---|
| Other settings | 4 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Type I or Ir pleuropulmonary blastoma | Complete surgical resection of the cystic lesion; adjuvant chemotherapy is optional and registry-guided; germline DICER1 testing for the child and first-degree relatives. | International PPB/DICER1 Registry; NCI PDQ | 94 | |
| All comers | Type II or III pleuropulmonary blastoma | Neoadjuvant or adjuvant multi-agent chemotherapy (ifosfamide, vincristine, dactinomycin, doxorubicin) with complete resection; radiotherapy for unresectable residual disease. | International PPB/DICER1 Registry recommendations (Cancer 2015) | 79 | |
| All comers | Tracheobronchial carcinoid or mucoepidermoid carcinoma | Bronchoscopic assessment and parenchyma-sparing surgical resection (sleeve resection); systemic therapy rarely needed. | — | ||
| All comers | DICER1 carriers | Surveillance per international consensus: chest imaging in infancy and early childhood, abdominal ultrasound, thyroid ultrasound, and awareness of ovarian and other syndrome tumours. | DICER1 surveillance consensus (Clinical Cancer Research 2018) | 94 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.